nt219
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 3, 2020 (NCT04474470)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
STAT3 inhibitor
- Insulin receptor substrate 1INHIBITOR
IRS1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06919666 | Phase 1/Phase 2 (Phase 2) | Jun 12, 2025 | University of Colorado, Denver |
| NCT04474470 | Phase 1/Phase 2 (Phase 2) | Sep 3, 2020 | TyrNovo Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TyrNovo Ltd. | For profit | 1 | 1 | 1 | 2020 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1